Long-term outcomes by clinical and molecular risk stratification in patients with medulloblastoma receiving risk-adapted therapy
Authors:
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality (L2510021)
- Natural Science Foundation of Beijing Municipality (L232079)
- Natural Science Foundation of Beijing Municipality (JQ24040)
- National Natural Science Foundation of China (82204127)
- National Natural Science Foundation of China (82573715)
- National Natural Science Foundation of China (82273343)
- National Science and Technology Major Project (2022ZD0210100)
- Capital Medical University (2025-B23)
- Capital Medical University (3100/12100208)
This publication has 45 references indexed in Scilit:
- From MDT to MTB: the paradigm revolution in pediatric cancer treatment in the era of precision medicineHolistic Integrative Oncology, 2025
- Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesActa Neuropathologica, 2019
- Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trialThe Lancet Oncology, 2018
- Acute toxicity of craniospinal irradiation with volumetric‐modulated arc therapy in children with solid tumorsPediatric Blood & Cancer, 2018
- Intertumoral Heterogeneity within Medulloblastoma SubgroupsCancer Cell, 2017
- Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational studyThe Lancet Oncology, 2016
- Risk stratification of childhood medulloblastoma in the molecular era: the current consensusActa Neuropathologica, 2016
- Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysisThe Lancet Oncology, 2016
- Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened InhibitionCancer Cell, 2014
- Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroupsActa Neuropathologica, 2011